Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Eli Lilly and Company
City of Hope Medical Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Exelixis
University of Pennsylvania
British Columbia Cancer Agency
Instituto do Cancer do Estado de São Paulo
Eli Lilly and Company
Eli Lilly and Company
University Hospital, Basel, Switzerland